EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Dennis Thomas iD, Vanessa M McDonald, Sean Stevens, Erin S Harvey, Melissa Baraket, Philip Bardin, Jeffrey J Bowden, Simon Bowler, Jimmy Chien, Li Ping Chung, Andrew Gillman, Mark Hew iD und 17 weitere

Allergy · 2024-02 · 79 (2) · 384-392

DOI: 10.1111/all.15867 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergy, online erschienen am 25.08.2023. Verfasst von Dennis Thomas und 28 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, Hunter Medical Research Institute Asthm…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline Australia, Novartis Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission.

Methods

This observational study included 453 severe asthma patients (41% male; mean age ± SD 55.7 ± 14.7 years) from two real‐world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5‐item Asthma Control Questionnaire (ACQ‐5) ≤1 at 12 months. We also assessed clinical remission plus optimization (post‐bronchodilator FEV1 ≥80%) or stabilization (post‐bronchodilator FEV1 not greater than 5% decline from baseline) of lung function at 12 months. Sensitivity analyses explored various cut‐offs of ACQ‐5/FEV1 scores. The predictors of clinical remission were identified.

Results

29.3% (73/249) of AMR and 22.8% (37/162) of AXR cohort met the criteria for clinical remission. When lung function criteria were added, the remission rates were reduced to 25.2% and 19.1%, respectively. Sensitivity analyses identified that the remission rate ranged between 18.1% and 34.9% in the AMR cohort and 10.6% and 27.2% in the AXR cohort. Better lung function, lower body mass index, mild disease and absence of comorbidities such as obesity, depression and osteoporosis predicted the odds of achieving clinical remission.

Conclusion

Biologic treatment with mepolizumab or omalizumab for severe asthma‐induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaBiological ProductsAntibodies, Monoclonal, HumanizedHumansMaleFemaleOmalizumabBronchodilator AgentsAustralia

Stichwörter der Autor:innen

asthmamepolizumabomalizumabremission

Substanzen

OmalizumabmepolizumabAnti-Asthmatic AgentsBronchodilator AgentsBiological ProductsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia.
  • Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
  • Lung and Sleep Medicine, Monash University and Medical Centre and Hudson Institute, Clayton, Victoria, Australia.
  • Respiratory and Sleep Services, Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia.

ORCID-Profile: Dennis Thomas, Mark Hew, Sandra Hodge, Joy Lee, Janet Rimmer, John W Upham

Förderung

  • GlaxoSmithKline Australia
  • Novartis Australia

Zitieren

APA

Thomas, D., McDonald, V. M., Stevens, S., Harvey, E. S., Baraket, M., Bardin, P., Bowden, J. J., Bowler, S., Chien, J., Chung, L. P., Gillman, A., Hew, M., Hodge, S., James, A., Jenkins, C., Katelaris, C. H., Katsoulotos, G. P., Langton, D., Lee, J., …, & Gibson, P. G. (2024). Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy, 79(2), 384-392. https://doi.org/10.1111/all.15867

Vancouver

Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024;79(2):384-392. doi:10.1111/all.15867

BibTeX
@article{Thomas2024,
  author = {Thomas, Dennis and McDonald, Vanessa M and Stevens, Sean and Harvey, Erin S and Baraket, Melissa and Bardin, Philip and Bowden, Jeffrey J and Bowler, Simon and Chien, Jimmy and Chung, Li Ping and Gillman, Andrew and Hew, Mark and Hodge, Sandra and James, Alan and Jenkins, Christine and Katelaris, Constance H and Katsoulotos, Gregory P and Langton, David and Lee, Joy and Marks, Guy and Peters, Matthew and Radhakrishna, Naghmeh and Reynolds, Paul N and Rimmer, Janet and Sivakumaran, Pathmanathan and Upham, John W and Wark, Peter and Yang, Ian A and Gibson, Peter G},
  title = {Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {2},
  pages = {384--392},
  doi = {10.1111/all.15867}
}
Kostenlos starten →